Clinical Reference Database
Evidence-based documentation on GLP-1 receptor agonist medications. Each article is reviewed by a board-certified endocrinologist and updated regularly to reflect current clinical evidence.
219 Evidence-Based Guides
7 Medications Covered
Monthly Review Cycle
Browse by Medication
Ozempic GLP-1 RA
Injectable GLP-1 receptor agonist for type 2 diabetes and weight management.
Mounjaro GLP-1/GIP
Dual-action incretin mimetic targeting both GLP-1 and GIP receptors.
Wegovy GLP-1 RA
Higher-dose semaglutide specifically approved for chronic weight management.
Semaglutide GLP-1 RA
The active compound in Ozempic, Wegovy, and Rybelsus formulations.
Tirzepatide GLP-1/GIP
Novel dual-incretin molecule used in Mounjaro and Zepbound.
Zepbound GLP-1/GIP
Tirzepatide formulation approved specifically for obesity treatment.
Rybelsus GLP-1 RA
Oral semaglutide tablet for type 2 diabetes management.
Recently Published
Does Mounjaro Cause Acid Reflux? An Endocrinologist Explains Mar 15 Does Mounjaro Cause Acne? An Endocrinologist Explains Mar 15 Does Mounjaro Cause Anxiety? An Endocrinologist Explains Mar 15 Does Mounjaro Cause Back Pain? An Endocrinologist Explains Mar 15 Does Mounjaro Cause Bloating? An Endocrinologist Explains Mar 15 Does Mounjaro Cause Brain Fog? An Endocrinologist Explains Mar 15 Does Mounjaro Cause Constipation? An Endocrinologist Explains Mar 15 Does Mounjaro Cause Depression? An Endocrinologist Explains Mar 15